AllSides Balanced Search reveals information and ideas from all sides of the political spectrum so you can get the full picture.
Jan 26 2021
News
Moderna’s COVID-19 Vaccine Works Against the New Mutant Strains. Is That Enough?
First, the good news: in a study published Jan. 25 on a preprint server, Moderna says its COVID-19 vaccine continues to protect against two of the major mutant strains of SARS-CoV-2 circulating around the world: one that was first identified in the U.K. (called B.1.1.7) and one first seen in South Africa (B.1.351).
Now, the not-so-good news. Blood from people vaccinated with the company
Time MagazineDec 15 2020
News
FDA review clears path for second coronavirus vaccine, this one developed by Moderna
By the end of the week, the United States could have two coronavirus vaccines.
A vaccine candidate developed by biotechnology company Moderna appears poised for regulatory clearance after a detailed data review by Food and Drug Administration scientists confirmed the two-shot regimen was 94 percent effective in a clinical trial and carried no serious safety concerns.
The FDA is
Washington PostNov 16 2020
News
Moderna’s coronavirus vaccine found to be nearly 95 percent effective in a preliminary analysis
Biotechnology firm Moderna announced Monday that a preliminary analysis shows its experimental coronavirus vaccine is nearly 95 percent effective at preventing illness, including severe cases — a striking initial result that leaves the United States with the prospect that two coronavirus vaccines could be available on a limited basis by the end of the year.
The news comes a week after
Washington PostNov 09 2022
News
Moderna Shot May Cause Double To Triple As Many Heart Problems As Pfizer, New Study Finds
Moderna’s COVID-19 shot may cause two to three times as many heart-related side effects as Pfizer’s, according to a new Canadian study.
The rates of myocarditis and pericarditis in individuals within 21 days of getting their second shot were 35.6 and 22.9 per million doses, respectively, for Moderna compared to 12.6 and 9.4 per million for Pfizer, the research found. The connection
The Daily CallerOct 14 2021
News
FDA advisory panel unanimously endorses Moderna’s Covid vaccine booster for some groups
AFood and Drug Administration advisory panel voted unanimously Thursday in favor of authorizing booster shots of the Moderna Covid-19 vaccine to people 65 and older, those 18 to 64 with risk factors for severe Covid-19, and those whose jobs put them at high risk of serious complications of Covid-19, such as health care workers.
After hours of deliberation, the Vaccines and Related
STATMay 18 2020
News
Moderna’s coronavirus vaccine shows encouraging early results in human safety trial
Moderna, the Massachusetts biotechnology company behind a leading effort to create a coronavirus vaccine, announced promising early results from its first human safety tests Monday. The company plans to launch a large clinical trial in July aimed at showing whether the vaccine works.
The company reported that in eight patients who had been followed for a month and a half, the vaccine at
Washington PostMar 29 2022
News
FDA authorizes fourth Pfizer and Moderna Covid vaccine doses for people age 50 and older
The Food and Drug Administration has authorized fourth Pfizer and Moderna Covid vaccine doses for everyone age 50 and older, amid uncertainty over whether an even more contagious version of omicron will cause another wave of infection in the U.S. as it has in Europe and China.
The FDA also said it authorized a second Pfizer booster shot for people age 12 and older who have compromised
CNBCMar 29 2022
News
FDA green lights 2nd booster of Pfizer, Moderna COVID shots for older Americans
The U.S. Food and Drug Administration on Tuesday authorized a second booster dose for people age 50 and older of the two most commonly used COVID-19 vaccines, citing data showing waning immunity and the risks posed by Omicron variants of the virus.
Reporting by Michael Erman in New Jersey and Manojna Maddipatla in Bangaluru, Additional reporting by Ahmed Aboulenein in Washington;
ReutersFeb 17 2022
News
Moderna CEO sees potential end of coronavirus pandemic on horizon, though says it will never be eradicated
Moderna CEO Stephane Bancel on Wednesday said the end of the coronavirus pandemic could be on the horizon.
“I think that is a reasonable scenario,” he told CNBC when asked whether he thought the pandemic was winding down. “There’s an 80% chance that as omicron evolves or SarsCov-2 virus evolves, we are going to see less and less virulent viruses.”
Moderna along with Pfizer
New York Daily NewsMar 04 2021
News
Good news about the 'Moderna arm' vaccine rash — it's no worse with second shot
There's good news about "Moderna arm," the raised, sometimes itchy red rash some people get a week or so after being vaccinated with Moderna's COVID-19 vaccine.
There were concerns people who experienced the annoying rash might have a worse reaction with the second dose. A report published Wednesday finds that's not the case – and most don't have any reaction at all the second time.
USA TODAY